ALT - CIK 0001326190
Altimmune, Inc. (ALT) reported net income of -$88.09M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$88.09M | +7.3% |
| FY 2024 | -$95.06M | -7.5% |
| FY 2023 | -$88.45M | -4.4% |
| FY 2022 | -$84.71M | +12.7% |
| FY 2021 | -$97.09M | -98.0% |
| FY 2020 | -$49.04M | -139.0% |
| FY 2019 | -$20.52M | +47.6% |
| FY 2018 | -$39.17M | +15.6% |
| FY 2017 |
Altimmune, Inc. (ALT) reported net income of -$88.09M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, Altimmune, Inc.'s net income declined from -$3.80M to -$88.09M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$46.43M |
| -318.7% |
| FY 2016 | -$11.09M | -222.2% |
| FY 2015 | -$3.44M | +65.4% |
| FY 2014 | -$9.96M | +15.0% |
| FY 2013 | -$11.72M | -138.2% |
| FY 2012 | -$4.92M | -29.6% |
| FY 2011 | -$3.80M | - |